Raj Chovatiya, MD, PhD: Social and Structural Disease-State Disparities in Inflammatory Skin Disease in Skin of Color

Dr. Chovatiya reviews one of his AAD sessions in which he discussed atopic dermatitis, hidradenitis suppurativa, and psoriasis in patients with skin of color. In these highlights from his expansive talk, Dr. Chovatiya notes that while the manifestations of these diseases are not biologically distinct between patients of different races, there are many social and structural disparities in these disease states that affect patients with skin of color that warrant continued research.

MORE COVERAGE FROM THE 2025 AAD ANNUAL MEETING

Christopher Bunick, MD, PhD: Clearing Up Questions Around Benzene in Benzoyl Peroxide Products

Dr. Bunick explores the discussion on benzene in benzoyl peroxide (BPO) products, including questions around ensuring products are meeting FDA regulations, what dermatologists can do to continue using BPO safely, and examples of manufacturers who are already implementing supply chain safeguards.

...

Steve Daveluy, MD: Using Cryoinsufflation in Patients with Hidradenitis Suppurativa

Dr. Daveluy provides tips and guidance for using cryoinsufflation in the treatment of HS.

...

Emmy Graber, MD: New Efficacy Evidence for Acne and Rosacea Devices

Dr. Graber discusses new evidence supporting the use of 1726nm lasers for the treatment of inflammatory and non-inflammatory acne, as well as pulsed-dye laser and intense pulsed light devices to address the erythema of rosacea.

...

Peter Lio, MD: Updates in AD and Diet

Dr. Lio discusses the nuances of approaching patient questions and misconceptions around dietary modifications and restrictions for atopic dermatitis.

...

Lisa Swanson, MD: What’s New in Pediatric Dermatology at AAD 2025

Dr. Swanson discusses the most exciting developments across pediatric atopic dermatitis, psoriasis, alopecia areata, vitiligo, and infantile hemangiomas.

...

Peter Lio, MD: Managing Itch in Patients with Cancer

Dr. Lio discusses several alternative approaches to managing itch in patients who are being treated for non-dermatologic cancers.

...

Christopher Bunick, MD, PhD: Antibiotic Update for Acne and Rosacea

Dr. Bunick provides a comprehensive update on using antibiotics for the treatment of acne and rosacea, including influences on gut health, antibiotic resistance, and efficacy compared to other acne treatments.

...

Jennifer Hsiao, MD: Recalcitrant Hidradenitis Suppurativa—What to do Next?

Dr. Hsiao discusses new and emerging therapies to help patients with HS that is unresponsive to treatment.

...

Steve Daveluy, MD: Pharm to Table: How Medications and Diet Interact

Dr. Daveluy reviews how diet can influence the effectiveness and side effects of certain dermatological drugs.

...

David Rosmarin, MD: How to Use Ruxolitinib Cream for Vitiligo

Dr. Rosmarin highlights his presentation from AAD 2025, in which he reviewed the optimal method for using ruxolitinib cream for vitiligo, touching on setting patient expectations, pigmentation timelines, and response rates among patient sub-groups, and navigating any potential side effects.

...

Iltefat Hamzavi, MD: Carbon Dioxide Laser for Hidradenitis Suppurativa

Dr. Hamzavi discusses key points from his presentation within the AAD 2025 session on surgical options for hidradenitis suppurativa.

...

Raj Chovatiya, MD, PhD: Chronic Hand Eczema at AAD 2025

Dr. Chovatiya discusses a symposium that he participated in at AAD 2025 focused on chronic hand eczema, reviewing prevalence, subtypes, morphology, and other important considerations for optimizing the treatment of CHE.

...

Iltefat Hamzavi, MD: Surgical Options for Vitiligo

Dr. Hamzavi reviews the correct patient candidate for surgical therapy for vitiligo and the different options available, including punch grafting, suction blister epidermal grafting, and non-cultured epidermal suspension.

...

Julien Seneschal, MD, PhD: Immune Pathogenesis of Vitiligo

In an overview from his AAD 2025 presentation, Dr. Seneschal reviews important dimensions of the pathogenesis of vitiligo that necessitate maintenance therapy.

...

Melinda Gooderham, MSc, MD, FRCPC: JAK Inhibitors for Psoriasis

Dr. Gooderham discusses JAK inhibition in the context of psoriasis treatment, including comparing the important difference between competitive inhibition and allosteric inhibition when using JAKs to treat psoriasis.

...

Aaron Drucker MD, SCM, FRCPC: A Network Meta-analysis of Systemic Therapies for Atopic Dermatitis

In a summary of one of his talks from AAD 2025, Dr. Drucker discusses the results from a network meta-analysis that provides insight beyond the primary literature regarding the efficacy of systemic therapies for AD, including oral JAK inhibitors and biologics.

...

The AAD © Brand and Content are created by the American Academy of Dermatology “All rights reserved.” Any reproduction or republication is strictly prohibited without prior authorization.

The content of the 2025 AAD Annual Meeting (the “Content”) is copyrighted by the American Academy of Dermatology (“AAD”). The Works, JCADTV Coverage from the 2025 AAD Annual Meeting, are made up of coverage interviews and summaries and are created from the Content of the AAD under a license between the AAD and Matrix Medical Communications (“MATRIX MEDICAL COMMUNICATIONS”), and MATRIX MEDICAL COMMUNICATIONS is solely responsible for their content. The license of any content by the AAD does not constitute or imply endorsement of any company or its goods, services, or written work products, and the AAD is not responsible for any errors or omissions in the translation or reproduction of the content.